Overview Between January 2025 and June 2026, 20 medicinal products entered the EU Joint Clinical Assessment (JCA) process, including seven medicines developed primarily by Chinese companies. These products represent [...]
A new article authored by CIRS' Dr Tina Wang and Dr Neil McAuslane, together with Prof Jin Wang of the OmniChain Med Institute, has been published in the September [...]
As pharmaceutical innovation becomes increasingly global, companies are pursuing multi-jurisdictional approvals and timely patient access through evolving regulatory and reimbursement pathways. In China, regulatory reforms and expanded use of [...]
All approved medicines have been rigorously assessed by regulatory authorities to ensure their benefits outweigh the risks. Today, pharmaceutical companies are increasingly focused on integrated global drug development strategies, [...]
China has made significant changes to its medicine regulatory system including: Regulatory reforms - since 2015, regulatory reforms have helped to eliminate application backlogs, improve review timelines and increase [...]
Changes have occurred in the organisation and procedural activities of the China Food and Drug Administration (CFDA) and the Centre for Drug Evaluation (CDE). Initiatives that were designed to [...]